A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab
Study of LNS8801 Alone or in Combination with Pembrolizumab in Patients with Advanced Cancer
Sponsor: Linnaeus Therapeutics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT8046
U.S. Govt. ID: NCT04130516
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to determine if a new investigational drug, LNS8801, is safe and helpful in patients with cancer that have not improved and where there are no additional standard treatment options. LNS8801 is an agonist of the G protein-coupled estrogen receptor (GPER), meaning that it can bind to this protein and turn on signaling inside the cell. Studies in animals have shown that increasing GPER activity can inhibit the growth of many types of cancer, shrink the cancer, and help the immune system remove the cancer from the body. Some patients will also receive LNS8801 in combination with pembrolizumab, which is an FDA-approved monoclonal antibody that is used to treat various types ofcancer by helping your immune system to fight cancer. Some patients will receive pembrolizumab to determine the effectivness of LNS8801 in treating cancer when given with and without pembrolizumab. Cancers include: bladder cancer, breast cancer, esophageal cancer, ovarian cancer, kidney cancer, liver cancer, lung cancer, lymphoma, melanoma, pancreatic cancer, prostate cancer, and soft tissue sarcoma.
This study is closed
Brian Henick, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with advanced cancer? Yes No
Have you received at least one prior cancer therapy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator